Protective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study DOI Creative Commons
Rundong Qin,

Yan Feng,

Huanping Zhang

и другие.

JMIR Public Health and Surveillance, Год журнала: 2024, Номер 10, С. e50846 - e50846

Опубликована: Окт. 16, 2024

Abstract Background Allergic diseases are associated with an increased susceptibility to respiratory tract infections. Although allergen immunotherapy (AIT) alters the course of allergies, there is limited evidence from clinical practice demonstrating its ability enhance host defense against pathogens. Objective The aim this study was investigate protective effect AIT viral infection in patients allergic rhinitis (AR) and asthma (AS) based on evidence. Methods A multicenter, questionnaire-based survey conducted during a tremendous surge COVID-19 cases between February 10, 2023, March 15, 81 centers across China recruiting healthy volunteers AR AS outcomes infection. Results Of 10,151 participants recruited survey, 3654 2192 who tested positive for were included analysis after screening. Overall, no significant differences observed volunteers. An additional 451 excluded due their use biologics as sole add-on treatment, leaving 3203 further analysis. them, 1752 undergoing routine medication treatment (RMT; RMT group), whereas 1057 394 receiving combination omalizumab (OMA) adjunct therapies RMT, respectively (AIT+RMT AIT+OMA+RMT groups). group showed milder symptoms, shorter recovery periods, lower likelihood hospitalization or emergency department visits than (all P <.05). After adjusting confounding factors, including demographic characteristics vaccination, remained factor time (adjusted odds ratio [OR] 0.62, 95% CI 0.52‐0.75; adjusted <.001) incidence OR 0.73, 0.54‐0.98; =.03). Furthermore, greater protection 0.51, 0.34‐0.74; AIT+RMT group. Conclusions Our multicenter observational provides valuable supporting AS.

Язык: Английский

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status DOI Creative Commons
Thomas B. Casale, Ana M. Giménez‐Arnau, Jonathan A. Bernstein

и другие.

Dermatology and Therapy, Год журнала: 2023, Номер 13(11), С. 2573 - 2588

Опубликована: Сен. 30, 2023

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by fluctuating natural history, complex mechanism action, and significant burden on patients, including effect quality life, development psychosocial disorders, range comorbidities. Recent international guidelines recommend therapeutic approach first-line treatment with second generation H1-antihistamines second-line biologic omalizumab. Here, salient aspects CSU current status data for omalizumab patients are reviewed, focus efficacy real-world effectiveness (including patient outcomes, response, relapse, remission), safety consideration risk anaphylaxis). The review also considers recent COVID-19, CSU, presents our perspective future needs. Overall, suggest that an effective well-tolerated provides benefits wide patients. skin condition causes raised red itchy bumps (known as hives) appear most days 6 weeks or longer. hives may be big small, warm to touch, come go, affect person's life. Omalizumab people living chronic can stop appearance hives. This article summarizes all information we know about urticaria, such how it works, successful at improving hives, long takes work, makes feel, safe is. in this shows helpful many urticaria.

Язык: Английский

Процитировано

17
Omalizumab Safety Concerns DOI
Thanai Pongdee,

James T. Li

Journal of Allergy and Clinical Immunology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Язык: Английский

Процитировано

6
COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation DOI Creative Commons
Giada Sambugaro, Elena Brambilla, Giulia Costanzo

и другие.

Life, Год журнала: 2024, Номер 14(3), С. 378 - 378

Опубликована: Март 13, 2024

This is a multicentric investigation involving two Italian centers that examined the clinical course of COVID-19 in patients receiving biological therapy targeting type 2 inflammation and those not biologicals. Since beginning pandemic, management respiratory allergic disorders potential impact most severe forms has been point uncertainty. Our aimed to compare vaccination an cohort with atopic caused by inflammation, such as eosinophilic asthma, chronic rhinosinusitis nasal polyposis (CRSwNP), dermatitis (AD), spontaneous urticaria (CSU). A questionnaire was given coming our outpatient clinic for first evaluation or follow-up visit, asking characteristics infection, ongoing during any relevant change, patient’s status. We enrolled 132 from centers; 62 were on at time infection (omalizumab 31%, mepolizumab 26%, benralizumab 19%, dupilumab 24%). The median age 56 (IQR 22.8) biologicals 48 26.5) (p = 0.028). groups comparable terms sex, body mass index (BMI), smoking history, systemic oral corticosteroid use (OCS). There no significant differences non-biological comorbidity between groups. had prevalence 87% 52% CRSwNP, 10% CSU, 6% AD. 93% 17% CSU. In work, we observed mAbs appeared be safe, worsening symptoms, prolongation increase hospitalizations. Between groups, there duration swab positivity 0.45) symptoms 0.38). During COVID-19, experienced common cold-like 0.038), dyspnea 0.016), more, but significant, asthma exacerbations, different Regarding status, increased number hospitalizations among unvaccinated both although difference did reach statistical significance. No reported safety issues adverse effects associated treatments COVID-19. showed against Coronavirus Disease 2019 are safe do main outcomes. Therefore, found signals suggesting anti-Th2 should discontinued SARS-CoV-2 infection. Controlled studies analysis, including data registries real-life studies, required draw firm conclusions regarding possible advantages anti-type could offer particular contexts, infections.

Язык: Английский

Процитировано

3
Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations DOI Creative Commons
Анна Старшинова, Anastasiia A. Borozinets,

Anastasia Kulpina

и другие.

Pathophysiology, Год журнала: 2024, Номер 31(2), С. 269 - 287

Опубликована: Май 27, 2024

Bronchial asthma (BA) continues to be a difficult disease diagnose. Various factors have been described in the development of BA, but date, there is no clear evidence for etiology this chronic disease. The emergence COVID-19 has contributed pandemic course and immunologic features. However, are unambiguous data on background after COVID-19. There correlation between various trigger that provoke bronchial asthma. It now obvious SARS-CoV-2 virus one provoking factors. affected Currently, understanding whether progresses during or infection. According results some studies, significant difference was identified people Mild moderate do not increase severity Nevertheless, oral steroid treatment hospitalization severe BA were associated with higher severity. influence infection protective causes accumulated experience omalizumab patients COVID-19, who received pandemic, strongly suggested continued safe may help prevent Targeted therapy use also reduce further studies needed prove effect omalizumab. Data analysis should persist, based varying degrees

Язык: Английский

Процитировано

3
Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics DOI Creative Commons

Sara Manti,

Michela Leotta,

F. D’Amico

и другие.

Biomedicines, Год журнала: 2025, Номер 13(3), С. 674 - 674

Опубликована: Март 10, 2025

Since the onset of COVID-19 pandemic, managing asthma has become significantly more challenging. Both national and international guidelines emphasize importance continuing prescribed medications to maintain control prevent exacerbations. However, emergence SARS-CoV-2 infection raised concerns about safety biologic therapies during acute episodes, necessitating a careful individualized approach their use. Biologic therapies, including omalizumab, dupilumab, mepolizumab, reslizumab, benralizumab, tezepelumab, which target specific pathways in severe asthma, have revolutionized management by improving symptom reducing exacerbation rates. Despite proven benefits, intersection therapy active prompted questions regarding potential immunomodulatory effects risks. This review aimed synthesize current literature on antiviral drugs asthmatic patients with infection, encompassing both pediatric adult populations.

Язык: Английский

Процитировано

0
COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)—a Randomized Controlled Clinical Trial DOI Creative Commons
Michelle Le, Lauren Khoury,

Yang Lu

и другие.

Open Forum Infectious Diseases, Год журнала: 2024, Номер 11(4)

Опубликована: Фев. 23, 2024

Omalizumab is an anti-immunoglobulin E monoclonal antibody used to treat moderate severe chronic idiopathic urticaria, asthma, and nasal polyps. Recent research suggested that omalizumab may enhance the innate antiviral response have anti-inflammatory properties. We aimed investigate efficacy safety of in adults hospitalized for coronavirus disease 2019 (COVID-19) pneumonia. This was a phase II randomized, double blind, placebo-controlled trial comparing with placebo (in addition standard care) patients COVID-19. The primary endpoint composite mechanical ventilation and/or death at day 14. Secondary endpoints included all-cause mortality 28, time clinical improvement, duration hospitalization. Of 41 recruited, 40 were randomized (20 received study drug 20 placebo). median age 74 years 55.0% male. associated 92.6% posterior probability reduction on 14 adjusted odds ratio 0.11 (95% credible interval 0.002-2.05). also 75.9% reduced 28 0.49 interval, 0.06-3.90). No statistically significant differences found improvement Numerically fewer adverse events reported group there no drug-related serious events. These results suggest could prove protective against support development III program investigating effect respiratory viral illnesses requiring hospital admission. ClinicalTrials.gov ID: NCT04720612.

Язык: Английский

Процитировано

2
COVID-19 and Its Impact on Common Diseases in the Allergy Clinics DOI
Emek Kocatürk, Elissa M. Abrams, Marcus Maurer

и другие.

The Journal of Allergy and Clinical Immunology In Practice, Год журнала: 2023, Номер 11(11), С. 3289 - 3303

Опубликована: Сен. 1, 2023

Язык: Английский

Процитировано

5
Protective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study DOI Creative Commons
Rundong Qin,

Yan Feng,

Huanping Zhang

и другие.

JMIR Public Health and Surveillance, Год журнала: 2024, Номер 10, С. e50846 - e50846

Опубликована: Окт. 16, 2024

Abstract Background Allergic diseases are associated with an increased susceptibility to respiratory tract infections. Although allergen immunotherapy (AIT) alters the course of allergies, there is limited evidence from clinical practice demonstrating its ability enhance host defense against pathogens. Objective The aim this study was investigate protective effect AIT viral infection in patients allergic rhinitis (AR) and asthma (AS) based on evidence. Methods A multicenter, questionnaire-based survey conducted during a tremendous surge COVID-19 cases between February 10, 2023, March 15, 81 centers across China recruiting healthy volunteers AR AS outcomes infection. Results Of 10,151 participants recruited survey, 3654 2192 who tested positive for were included analysis after screening. Overall, no significant differences observed volunteers. An additional 451 excluded due their use biologics as sole add-on treatment, leaving 3203 further analysis. them, 1752 undergoing routine medication treatment (RMT; RMT group), whereas 1057 394 receiving combination omalizumab (OMA) adjunct therapies RMT, respectively (AIT+RMT AIT+OMA+RMT groups). group showed milder symptoms, shorter recovery periods, lower likelihood hospitalization or emergency department visits than (all P <.05). After adjusting confounding factors, including demographic characteristics vaccination, remained factor time (adjusted odds ratio [OR] 0.62, 95% CI 0.52‐0.75; adjusted <.001) incidence OR 0.73, 0.54‐0.98; =.03). Furthermore, greater protection 0.51, 0.34‐0.74; AIT+RMT group. Conclusions Our multicenter observational provides valuable supporting AS.

Язык: Английский

Процитировано

1